<DOC>
	<DOCNO>NCT00119301</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , methotrexate , trimetrexate glucuronate , leucovorin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I trial study side effect best dose trimetrexate glucuronate give together methotrexate leucovorin treat patient refractory recurrent osteosarcoma .</brief_summary>
	<brief_title>Methotrexate , Trimetrexate Glucuronate , Leucovorin Treating Patients With Refractory Recurrent Osteosarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose trimetrexate glucuronate administer high-dose methotrexate leucovorin calcium patient refractory recurrent high-grade osteosarcoma . Secondary - Determine dose-limiting toxic effect regimen patient . - Determine , preliminarily , antitumor activity regimen patient . OUTLINE : This dose-escalation study trimetrexate glucuronate . Patients receive high-dose methotrexate IV 4 hour day 1 8 oral trimetrexate glucuronate twice daily day 2-6 9-13 . Patients also receive leucovorin calcium IV continuously 24 hour orally 2 4 time daily day 9-14 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos trimetrexate glucuronate maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A maximum 18 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Trimetrexate</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant osteosarcoma Highgrade disease Recurrent refractory disease prior standard chemotherapy comprise methotrexate , doxorubicin , cisplatin , ifosfamide No lowgrade osteosarcoma No parosteal periosteal sarcoma No osteosarcoma arise premalignant bony lesion ( e.g. , Paget 's disease ) OR prior radiotherapy field No symptomatic know brain leptomeningeal involvement PATIENT CHARACTERISTICS : Age 1 35 Performance status Karnofsky 70100 % ( patient &gt; 16 year age ) Lansky 70100 % ( patient ≤ 16 year age ) Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 75,000/mm^3 Hepatic Bilirubin ≤ 1.5 time normal AST ALT ≤ 5 time normal Albumin ≥ 2 g/dL No clinically significant liver disease Renal Creatinine ≤ 1.5 time normal OR Creatinine clearance radioisotope glomerular filtration rate ≥ low limit normal Cardiovascular Shortening fraction ≥ 27 % echocardiogram OR Ejection fraction ≥ 50 % gate radionuclide study No congestive heart failure No angina pectoris No myocardial infarction within past year No uncontrolled arterial hypertension No uncontrolled arrhythmias Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history significant neurological psychiatric disorder No active infection No symptomatic peripheral neuropathy ≥ grade 2 No serious illness medical condition PRIOR CONCURRENT THERAPY : Biologic therapy At least 7 day since prior biologic therapy At least 6 month since prior allogeneic stem cell transplantation AND evidence active graftversushost disease No concurrent sargramostim ( GMCSF ) Chemotherapy See Disease Characteristics More 2 week since prior myelosuppressive chemotherapy ( 4 week nitrosoureas ) Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 2 week since prior local palliative radiotherapy ( small port ) At least 6 month since prior craniospinal radiotherapy At least 6 month since prior radiotherapy ≥ 50 % pelvis At least 6 week since prior substantial radiotherapy bone marrow Surgery Not specify Other Recovered prior therapy More 30 day since prior concurrent investigational drug More 30 day since prior concurrent participation another clinical trial No concurrent medication may interact study drug</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>recurrent osteosarcoma</keyword>
</DOC>